Middle East and Africa Urinary Tract Infection (UTI) Drugs Market Research Report- Forecast to 2027

Middle East and Africa Urinary Tract Infection (UTI) Drugs Market Information by Drug Class (Quinolones, Aminoglycosides, β-lactam, Azoles and others), Clinical Indications (Urethritis, Cystitis, Pyelonephritis) and End User (Hospitals and Self-administered) - Forecast to 2027

ID: MRFR/Pharma/1900-HCR | February 2021 | Region: Global | 84 pages

Middle East and Africa Urinary Tract Infection (UTI) Drugs Market Synopsis:


Market Scenario:


Urinary tract infection (UTI) is the infection of the lower or upper urinary tract generally due to escherichia coli although other bacteria and fundi may be causative organisms. Symptoms include pain with  urination, frequent urination and feeling the need to urinate despite having an empty bladder. Risk factors that may cause UTI include female anatomy, sexual intercourse, diabetes, obesityetc. World Health Organization (WHO) estimates that approximately 50 % of women suffer from UTI at some point of time in their lives resulting in more than 1 million hospitalizations per year. WHO estimates the annual cost of UTI infections treatment to be greater than $1 billion. It has further been stated that 1% of boys and 3-8% of girls are diagnosed with UTI. .


The Middle East and African urinary tract infection (UTI) drugs market is growing due to factors such as catheter associated UTI, hospital borne infections (nosocomial infections), child birth, old age, obesity, growing health awareness especially about women health etc. However, there remain market constraints such as drug resistance, unmet clinical needs, increasing incidence of chronic diseases etc. Another prominent restrain is the excellent efficacy of present antibiotics specially the quinolones. However the rise of drug resistance has negated this constraint and had opened doors to new drug development as a good strategy for UTI treatment.


Taking all these factors into consideration, the Middle East and Africa UTI drugs market had reached around $ 992.84 million from $ 769 million in 2015 by growing at the CAGR of 4.35%.


Study Objectives Middle East and Africa Urinary Tract Infection (UTI) Drugs Market:



  • To provide detail analysis of the market structure along with forecast for the next 5 years about various segments and sub segments of the Middle East and African UTI Drugs market.

  • To provide insights about factors affecting the market growth.

  • To analyze the market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.

  • To provide past and estimated future revenue of Middle East and Africa UTI drugs market’s segments and sub-segments.

  • To provide country level analysis of the market with respect to the current market size and future growth prospect.

  • To provide country level analysis of the market’s segments which includes by drug class, by clinical indication, by end users and other sub segments.

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies and drawing a competitive landscape of the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments taking place globally.


Middle East and Africa Urinary Tract Infection (UTI) Drugs Market, by Product Type, 2015 (%): 


 Middle East and Africa UTI Drugs Market, by Product Type, 2015


Intended Audience



  • UTI drugs manufacturers

  • UTI drugs suppliers

  • Private research laboratories

  • Research and development (R&D) companies

  • Market research and consulting service providers

  • Government research laboratories

  • Contract manufacturing organizations


Key Players of Middle East and Africa UTI Drugs Market:


Some of the key players in Middle East and Africa Urinary Tract Infection (UTI) Drugs Market are: Bayer AG, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Cipla Inc., Dr. Reddy’s Laboratories Ltd. and others.


Segments:


Middle East and Africa Urinary Tract Infection (UTI) Drugs Market has been segmented on the basis of drug class which comprises of quinolones, aminoglycosides, β-lactam, azoles and others. On the basis of clinical indications Middle East and Africa Urinary Tract Infection (UTI) Drugs Market is segmented into urethritis, cystitis, and pyelonephritis. On the basis of end users the Middle East and Africa Urinary Tract Infection (UTI) Drugs Market is segmented into hospitals and self-administered.


Regional Analysis of Middle East and Africa UTI Drugs Market:


UAE is the largest market of UTI drugs Middle East and Africa Urinary Tract Infection (UTI) Drugs Market closely followed by Egypt. South Africa ranks high in the agendas of many Indian based pharmaceutical firms. The rest of African market is the fastest growing Middle East and Africa Urinary Tract Infection (UTI) Drugs Market since there are huge unmet medical needs.


The report about Middle East and Africa Urinary Tract Infection (UTI) Drugs Market by Market Research Future comprises extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future Middle East and Africa Urinary Tract Infection (UTI) Drugs Market size with respect to value & volume, technological advancement, macro economical and governing factors in the Middle East and Africa Urinary Tract Infection (UTI) Drugs Market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of different markets segments and regions.



Table of Contents

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure:

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s Five Forces Model

4.1.1 Bargaining Power of Suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

5 Middle East and Africa UTI Drugs Market, by Drug Class

5.1 Introduction

5.1.1 Quinolones

5.1.2 Aminoglycosides

5.1.3 β-lactam

5.1.4 Azoles

5.1.5 Others

6 Middle East and Africa UTI Drugs Market, by Clinical Indications

6.1 Introduction

6.1.1 Urethritis

6.1.2 Cystitis

6.1.3 Pyelonephritis

7 Middle East and Africa UTI Drugs Market, by End User

7.1 Introduction

7.1.1 Hospitals

7.1.3 Self-administered

8 Middle East and Africa UTI Drugs Market, by Country

8.1 Introduction

8.2 UAE

8.3 Egypt

8.4 Saudi Arabia

8.5 Kuwait

8.6 Qatar

8.7 Oman

9 Company Landscape

9.1 Introduction

9.1.1 Mergers Acquisitions

9.1.2 Collaborations

9.1.3 Release/New Product Launches

9.1.4 Other (Expansion, Updates, Partnership)

10 Company Profile

10.1 Bayer AG

10.1.1 Company Overview

10.1.2 Product/Business Segment Overview

10.1.3 Financials

10.1.4 Key Developments

10.1.5 SWOT Analysis

10.2 Novartis AG

10.2.1 Overview

10.2.2 Product/Business Segment Overview

10.2.3 Financials

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 Pfizer Inc.

10.3.1 Overview

10.3.2 Product/Business Segment Overview

10.3.3 Financials

10.3.4 Key Developments

10.3.5 SWOT Analysis

10.4 F. Hoffmann-La Roche Ltd

10.4.1 Overview

10.4.2 Product/Business Segment Overview

10.4.3 Financials

10.4.4 Key Developments

10.4.5 SWOT Analysis

10.5 AstraZeneca

10.5.1 Overview

10.5.2 Product/Business Segment Overview

10.5.3 Financials

10.5.4 Key Developments

10.5.5 SWOT Analysis

10.6 Cipla Inc.

10.6.1 Overview

10.6.2 Product/Business Segment Overview

10.6.3 Financials

10.6.4 Key Developments

10.6.5 SWOT Analysis

10.7 Dr. Reddy’s Laboratories Ltd

10.7.1 Overview

10.7.2 Product/Business Segment Overview

10.7.3 Financials

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Others

11 Appendix

List of Tables

TABLE 1 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, 2020-2027 (USD MILLION)

TABLE 2 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY CLINICAL INDICATIONS, 2020-2027 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY DRUG CLASS

FIGURE 4 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY CLINICAL INDICATIONS

FIGURE 5 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY END USER

FIGURE 6 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY REGION

FIGURE 7 MIDDLE EAST AND AFRICA UTI DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)